drugset / Trial / NCT05515458
Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with renal impairment compared to subjects with normal renal function.
Timeline
- Start
- 2022-11-20
- Primary completion
- 2023-07-19
- Completion
- 2023-07-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chiglitazar | Unknown | 48 mg | Oral |